Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Assets (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Current Assets for 7 consecutive years, with $357.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 43.04% to $357.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $357.5 million, a 43.04% increase, with the full-year FY2025 number at $357.5 million, up 43.04% from a year prior.
  • Current Assets was $357.5 million for Q4 2025 at Fulcrum Therapeutics, up from $205.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $357.5 million in Q4 2025 to a low of $128.5 million in Q2 2021.
  • A 5-year average of $233.9 million and a median of $230.1 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 89.1% in 2021, then dropped 28.03% in 2024.
  • Fulcrum Therapeutics' Current Assets stood at $226.0 million in 2021, then decreased by 8.18% to $207.5 million in 2022, then rose by 16.71% to $242.2 million in 2023, then rose by 3.19% to $249.9 million in 2024, then surged by 43.04% to $357.5 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Current Assets are $357.5 million (Q4 2025), $205.9 million (Q3 2025), and $219.4 million (Q2 2025).